Clinical Implications of Peripheral Myelin Protein 22 for Nerve Compression and Neural Regeneration: A Review

ABSTRACT

Peripheral myelin protein 22 (PMP22) is a major component of the peripheral myelin sheath. The PMP22 gene is located on chromosome 17p11.2, and defects in PMP22 gene have been implicated in several common inherited peripheral neuropathies. Hereditary neuropathy with liability to pressure palsies (HNPP), Charcot-Marie Tooth disease type 1A (CMT1A), Dejerine-Sottas syndrome, and congenital hypomyelinating neuropathy are all associated with defects in PMP22 gene. The disease phenotypes mirror the range of expression of PMP22 due to the corresponding genetic defect. HNPP, characterized by a milder recurrent episodic focal demyelinating neuropathy, is attributed to a deletion leading to PMP22 underexpression. On the other end of the spectrum, CMT1A leads to a more uniform demyelination and axonal loss, resulting in severe progressive distal weakness and paresthesias; it is due to a duplication at 17p11.2 leading to PMP22 overexpression. Additional point mutations result in varying phenotypes due to dysfunction of the resultant PMP22 protein. All inherited neuropathies are diagnosed with a combination of physical findings on examination, electromyography, sural nerve biopsies, and genetic testing. Treatment and management of these disorders differ depending on the underlying genetic defect, nerves involved, and resulting functional impairments. A review of current literature elucidates clinical, microsurgical implications, and management of patients with PMP22-related neuropathy.

KEYWORDS

Peripheral myelin protein 22 - hereditary neuropathy with liability to pressure palsies - Charcot-Marie-Tooth disease - neurolysis

REFERENCES

• 1 Snipes G J, Suter U, Welcher A A, Shooter E M. Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13).  J Cell Biol. 1992;  117 225-238
• 2 Suter U, Welcher A A, Snipes G J. Progress in the molecular understanding of hereditary peripheral neuropathies reveals new insights into the biology of the peripheral nervous system.  Trends Neurosci. 1993;  16 50-56
• 3 Taylor V, Welcher A A, Program A E, Suter U. Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family.  J Biol Chem. 1995;  270 28824-28833
• 4 Suter U, Scherer S S. Disease mechanisms in inherited neuropathies.  Nat Rev Neurosci. 2003;  4 714-726
• 5 Pareek S, Suter U, Snipes G J, Welcher A A, Shooter E M, Murphy R A. Detection and processing of peripheral myelin protein PMP22 in cultured Schwann cells.  J Biol Chem. 1993;  268 10372-10379
• 6 Patel P I, Roa B B, Welcher A A et al.. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A.  Nat Genet. 1992;  1 159-165
• 7 Ohsawa Y, Murakami T, Miyazaki Y, Shirabe T, Sunada Y. Peripheral myelin protein 22 is expressed in human central nervous system.  J Neurol Sci. 2006;  247 11-15
• 8 Parmantier E, Cabon F, Braun C, D'Urso D, Müller H W, Zalc B. Peripheral myelin protein-22 is expressed in rat and mouse brain and spinal cord motoneurons.  Eur J Neurosci. 1995;  7 1080-1088
• 9 Sanahuja J, Franco E, Rojas-García R et al.. Central nervous system involvement in hereditary neuropathy with liability to pressure palsies: description of a large family with this association.  Arch Neurol. 2005;  62 1911-1914
• 10 Tackenberg B, Möller J C, Rindock H et al.. CNS involvement in hereditary neuropathy with pressure palsies (HNPP).  Neurology. 2006;  67 2250-2252
• 11 Amato A A, Barohn R J. Hereditary neuropathy with liability to pressure palsies: association with central nervous system demyelination.  Muscle Nerve. 1996;  19 770-773
• 12 Dacković J, Rakocević-Stojanović V, Pavlović S et al.. Hereditary neuropathy with liability to pressure palsies associated with central nervous system myelin lesions.  Eur J Neurol. 2001;  8 689-692
• 13 Schneider C, Reiners K, Friedl W, Ebner R, Toyka K V. Involvement of the visual pathway in hereditary neuropathy with liability to pressure palsies.  J Neurol. 2000;  247 222-223
• 14 Naef R, Suter U. Many facets of the peripheral myelin protein PMP22 in myelination and disease.  Microsc Res Tech. 1998;  41 359-371
• 15 Stögbauer F, Young P, Kuhlenbäumer G, De Jonghe P, Timmerman V. Hereditary recurrent focal neuropathies: clinical and molecular features.  Neurology. 2000;  54 546-551
• 16 Patel P I, Lupski J R. Charcot-Marie-Tooth disease: a new paradigm for the mechanism of inherited disease.  Trends Genet. 1994;  10 128-133
• 17 Nicholson G A, Valentijn L J, Cherryson A K et al.. A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies.  Nat Genet. 1994;  6 263-266
• 18 Hodapp J A, Carter G T, Lipe H P, Michelson S J, Kraft G H, Bird T D. Double trouble in hereditary neuropathy: concomitant mutations in the PMP-22 gene and another gene produce novel phenotypes.  Arch Neurol. 2006;  63 112-117
• 19 Zoidl G, Blass-Kampmann S, D'Urso D, Schmalenbach C, Müller H W. Retroviral-mediated gene transfer of the peripheral myelin protein PMP22 in Schwann cells: modulation of cell growth.  EMBO J. 1995;  14 1122-1128
• 20 Fabbretti E, Edomi P, Brancolini C, Schneider C. Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: its relation to the demyelinating peripheral neuropathy CMT1A.  Genes Dev. 1995;  9 1846-1856
• 21 Vallat J M, Sindou P, Preux P M et al.. Ultrastructural PMP22 expression in inherited demyelinating neuropathies.  Ann Neurol. 1996;  39 813-817
• 22 Sahenk Z, Chen L, Freimer M. A novel PMP22 point mutation causing HNPP phenotype: studies on nerve xenografts.  Neurology. 1998;  51 702-707
• 23 Shaffer L G, Kennedy G M, Spikes A S, Lupski J R. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory.  Am J Med Genet. 1997;  69 325-331
• 24 Chance P F, Abbas N, Lensch M W et al.. Two autosomal dominant neuropathies result from reciprocal DNA duplication/deletion of a region on chromosome 17.  Hum Mol Genet. 1994;  3 223-228
• 25 Sahenk Z, Chen L, Mendell J R. Effects of PMP22 duplication and deletions on the axonal cytoskeleton.  Ann Neurol. 1999;  45 16-24
• 26 Lupski J R. An inherited DNA rearrangement and gene dosage effect are responsible for the most common autosomal dominant peripheral neuropathy: Charcot-Marie-Tooth disease type 1A.  Clin Res. 1992;  40 645-652
• 27 Lupski J R. Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity.  Pediatr Res. 1999;  45 159-165
• 28 Gochard A, Guennoc A M, Praline J, Malinge M C, de Toffol B, Corcia P. Bilateral hand amyotrophy with PMP-22 gene deletion.  Eur J Neurol. 2007;  14 115-116
• 29 Roa B B, Garcia C A, Suter U et al.. Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene.  N Engl J Med. 1993;  329 96-101
• 30 Li J, Ghandour K, Radovanovic D et al.. Stoichiometric alteration of PMP22 protein determines the phenotype of hereditary neuropathy with liability to pressure palsies.  Arch Neurol. 2007;  64 974-978
• 31 Rautenstrauss B, Fuchs C, Liehr T, Grehl H, Murakami T, Lupski J R. Visualization of the CMT1A duplication and HNPP deletion by FISH on stretched chromosome fibers.  J Peripher Nerv Syst. 1997;  2 319-322
• 32 Gouider R, LeGuern E, Gugenheim M et al.. Clinical, electrophysiologic, and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletion.  Neurology. 1995;  45 2018-2023
• 33 Mariman E C, Gabreëls-Festen A A, van Beersum S E et al.. Prevalence of the 1.5-Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies.  Ann Neurol. 1994;  36 650-655
• 34 Hanemann C O, D'Urso D, Gabreëls-Festen A A, Müller H W. Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A.  Brain. 2000;  123 (Pt 5) 1001-1006
• 35 Mouton P, Tardieu S, Gouider R et al.. Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion.  Neurology. 1999;  52 1440-1446
• 36 Reilly M M. Sorting out the inherited neuropathies.  Pract Neurol. 2007;  7 93-105
• 37 Celik Y, Kilinçer C, Hamamcioğlu M K et al.. Hereditary neuropathy with liability to pressure palsies in a Turkish patient (HNPP): a rare cause of entrapment neuropathies in young adults.  Turk Neurosurg. 2008;  18 82-84
• 38 Farooq M U, Martin J H, Andary M T. Unusual presentation of hereditary neuropathy with liability to pressure palsies.  J Brachial Plex Peripher Nerve Inj. 2008;  3 2
• 39 Li J, Bai Y, Ghandour K et al.. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside.  Brain. 2005;  128(Pt 5) 1168-1177
• 40 Guyton G P. Current concepts review: orthopaedic aspects of Charcot-Marie-Tooth disease.  Foot Ankle Int. 2006;  27 1003-1010
• 41 Timmerman V, Nelis E, Van Hul W et al.. The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication.  Nat Genet. 1992;  1 171-175
• 42 Hanemann C O, Müller H W. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.  Trends Neurosci. 1998;  21 282-286
• 43 Hanemann C O, Stoll G, D'Urso D et al.. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.  J Neurosci Res. 1994;  37 654-659
• 44 Sambuughin N, de Bantel A, McWilliams S, Sivakumar K. Deafness and CMT disease associated with a novel four amino acid deletion in the PMP22 gene.  Neurology. 2003;  60 506-508
• 45 Padua L, Aprile I, Cavallaro T Italian CMT QoL Study Group et al. Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study.  Neurol Sci. 2008;  29 157-162
• 46 Padua L, Cavallaro T, Pareyson D, Quattrone A, Vita G, Schenone A. Italian CMT QoL Study Group . Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings.  Neurol Sci. 2008;  29 193-194
• 47 Padua L, Shy M E, Aprile I et al.. Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A.  J Peripher Nerv Syst. 2008;  13 64-70
• 48 Nishimura T, Yoshikawa H, Fujimura H, Sakoda S, Yanagihara T. Accumulation of peripheral myelin protein 22 in onion bulbs and Schwann cells of biopsied nerves from patients with Charcot-Marie-Tooth disease type 1A.  Acta Neuropathol. 1996;  92 454-460
• 49 Hayasaka K, Himoro M, Sawaishi Y et al.. De novo mutation of the myelin P0 gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III).  Nat Genet. 1993;  5 266-268
• 50 Ikegami T, Ikeda H, Aoyama M et al.. Novel mutations of the peripheral myelin protein 22 gene in two pedigrees with Dejerine-Sottas disease.  Hum Genet. 1998;  102 294-298
• 51 Ikegami T, Nicholson G, Ikeda H et al.. A novel homozygous mutation of the myelin Po gene producing Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III).  Biochem Biophys Res Commun. 1996;  222 107-110
• 52 Ikegami T, Nicholson G, Ikeda H et al.. De novo mutation of the myelin Po gene in Déjérine-Sottas disease (hereditary motor and sensory neuropathy type III): two amino acid insertion after Asp 118.  Hum Mutat. 1998;  (S 01) S103-S105
• 53 Roa B B, Dyck P J, Marks H G, Chance P F, Lupski J R. Dejerine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene.  Nat Genet. 1993;  5 269-273
• 54 Chandra S R, Kalpana D, Radhakrishnan V V, Kannan S R. Congenital hypomyelinating neuropathy.  Indian Pediatr. 2003;  40 1084-1087